Arrowhead Pharmaceuticals Inc. (ARWR) reached a new 52-week high of $31.13, capping off a strong upward trend that has seen the stock gain over 85% in the past six months and more than 55% year-to-date. The surge reflects growing confidence in the company's RNA interference or RNAi platform, late-stage pipeline progress, and its lead candidate, plozasiran, which is currently under FDA review with a PDUFA action date set for November 18, 2025.
The stock closed Friday's regular session at $29.72, with intraday trading ranging between $29.51 and $31.13, supported by a volume of over 3 million shares, well above its average of 2.32 million shares. Arrowhead now commands a market capitalization of about $4.11 billion.
For comments and feedback: editorial@rttnews.com